Strategic partnership drives life sciences expansion in South Korea

CN Bio, a global innovator in organ-on-a-chip (OOC) technology, has signed a distribution agreement with South Korea-based Scinco to extend access to its human-relevant research platforms across the Asia-Pacific region. The deal enhances CN Bio’s sales and technical support capabilities in one of Asia’s most dynamic biotech hubs.

With demand rising for non-animal, new approach methodologies (NAMs) in drug discovery, CN Bio’s benchtop PhysioMimix® systems offer pharmaceutical and biotech researchers advanced tools for improving the accuracy and efficiency of preclinical studies. These models replicate human physiology to provide better insights into drug safety, efficacy, and disease mechanisms - helping to reduce clinical failure rates and reliance on animal testing.

The agreement with Scinco follows a surge of investment in South Korea’s biotech sector, including billion-dollar licensing deals and the launch of a national fund to back high-tech industries. It builds on CN Bio’s ongoing APAC expansion, which recently saw the appointment of a distributor in Japan.

“South Korea is one of the most exciting life science markets in the region,” said Dr Paul Brooks, CEO of CN Bio. “Partnering with Scinco ensures we’re well-positioned to support researchers with world-class OOC systems that align with emerging regulatory priorities and scientific needs.”

Soo Min Choi, Director at Scinco, added: “This partnership reflects our commitment to bringing cutting-edge technologies to Korean researchers. As global demand for NAMs grows, CN Bio’s systems will play a critical role in shaping the future of drug development.” 

More information online